MedTrace Logo

Sacral Neuromodulation in Neurogenic Patients

NCT05688644 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-01-18

No results posted yet for this study

Summary

The goal of this observational study is to evaluate efficacy and safety of sacral neuromodulation in neurogenic patients compared to non-neurogenic (idiopathic) patients. \[. The main question\[s\] it aims to answer are:

* determine efficacy and safety of the therapy in neurogenic patients.
* compare outcomes of the therapy to idiopathic patients.

If there is a comparison group: Researchers will compare the outcomes of the therapy between the neurogenic and non-neurogenic subset of patients.

Conditions

  • Neurogenic Bladder
  • Neurogenic Bowel
  • Urge Incontinence
  • Overactive Bladder
  • Retention, Urinary
  • Fecal Incontinence

Interventions

DEVICE

InterStim II

Sacral neuromodulation

Sponsors & Collaborators

  • Omri Schwarztuch Gildor

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-19
Primary Completion
2023-12-31
Completion
2024-12-31
FDA Device
Yes

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05688644 on ClinicalTrials.gov